Investing.com - Axsome Therapeutics (NASDAQ:AXSM) Inc reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Axsome ...

Axsome Therapeutics, Inc. (NASDAQ ... This article provides a comprehensive analysis of Axsome's current position, future prospects, and potential challenges in the competitive CNS drug market.

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...

Ratings for Axsome Therapeutics AXSM were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Investors in Axsome Therapeutics Inc (Symbol: AXSM) saw new options become available this week, for the September 19th expiration. One of the key data points that goes into the price an option ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth ... In conclusion, Axsome Therapeutics presents a compelling investment case with its strong commercial ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth. AXS-07 for acute migraine ... In conclusion, Axsome Therapeutics presents a compelling investment case with its ...